Market Place
Sourcing Support
Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences
03 Jan 2023 //
PR NEWSWIRE
Oyster Point Pharma Reports Inducement Grants Under Nasdaq Listing
02 Dec 2022 //
GLOBENEWSWIRE
Viatris jumps into ophthalmology arena with pair of buyouts worth up to $750M
08 Nov 2022 //
FIERCEPHARMA
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company
07 Nov 2022 //
GLOBENEWSWIRE
Oyster Point Pharma, Reports Inducement Grants Under Nasdaq Listing
04 Oct 2022 //
GLOBENEWSWIRE
Oyster Point Pharma to Present New Scientific Analyses at World Cornea
27 Sep 2022 //
GLOBENEWSWIRE
Oyster Point Pharma Reports Inducement Grants Under Nasdaq Listing Rule
07 Sep 2022 //
GLOBENEWSWIRE
Oyster to Present Analyses at the Women in Ophthalmology Summer Symposium
25 Aug 2022 //
GLOBENEWSWIRE
Oyster Announces TYRVAYA To Be Covered By the Largest Medicare Pharmacy
17 Aug 2022 //
GLOBENEWSWIRE
Oyster Point plows ahead with 50 layoffs under cost strategy
12 Aug 2022 //
FIERCE BIOTECH
Oyster Point Pharma Reports Q2 2022 Rusult and Recent Business Highlights
11 Aug 2022 //
GLOBENEWSWIRE
Oyster Point Pharma To Report Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA
27 Jul 2022 //
GLOBENEWSWIRE
Oyster Point Pharma Announces Operating Expense Streamlining Plan
28 Jun 2022 //
GLOBENEWSWIRE
Oyster Point Pharma Research Selected for Top 5 Poster Session at AOAO
15 Jun 2022 //
GLOBENEWSWIRE
Oyster Point Pharma Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Oyster Point Pharma To Report First Quarter 2022 Financial Results
03 May 2022 //
GLOBENEWSWIRE
Oyster Point Pharma to Present New Analyses at ARVO 2022
27 Apr 2022 //
GLOBENEWSWIRE
Oyster Point Pharma to Present New Clinical Data at the ASCRS
19 Apr 2022 //
GLOBENEWSWIRE
Oyster Point Pharma says Retirement of William J. Link From Board of Directors
17 Mar 2022 //
GLOBENEWSWIRE
Oyster Point Pharma to Participate in Cowen 42nd Annual Health Care Conference
01 Mar 2022 //
GLOBENEWSWIRE
Oyster Point Pharma Reports Q4 and Full Year 2021 Financial Results
24 Feb 2022 //
GLOBENEWSWIRE
Oyster Point Pharma Announces TYRVAYA Nasal Spray Now Covered by Express Scripts
22 Feb 2022 //
GLOBENEWSWIRE
Oyster Point Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Jan 2022 //
GLOBENEWSWIRE
Oyster Expands Executive Leadership Team to Support Commercialization of Tyrvaya
24 Nov 2021 //
GLOBENEWSWIRE
Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3
15 Nov 2021 //
GLOBENEWSWIRE
Oyster’s TYRVAYA Nasal Spray is Now Available at U.S. Regional Wholesalers
03 Nov 2021 //
GLOBENEWSWIRE
Oyster Point Pharma to Present Data at the American Academy of Optometry
02 Nov 2021 //
GLOBENEWSWIRE
FDA OKs inhaled version of Chantix for a common eye disease
19 Oct 2021 //
ENDPTS
Oyster Point`s Drug Becomes First FDA-Approved Nasal Spray to Treat Dry Eyes
18 Oct 2021 //
USNEWS
Aerie brushes off dry eye trial failure
16 Sep 2021 //
EVALUATE
Chinese startup acquires rights to Oyster Point`s eye disease nasal spray
06 Aug 2021 //
ENDPTS
Oyster Point Pharma Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Oyster Point Pharma Announces Exclusive License Agreement with Ji Xing Pharma
05 Aug 2021 //
GLOBENEWSWIRE
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing
02 Aug 2021 //
GLOBENEWSWIRE
Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors
02 Aug 2021 //
GLOBENEWSWIRE
Oyster Point Announces Preclinical Data Highlighting Activity of OC-01 and OC-02
01 Jul 2021 //
GLOBENEWSWIRE
Oyster Point Pharma Provides Key Supply Chain Insight For OC-01 Nasal Spray
29 Jun 2021 //
GLOBENEWSWIRE
Oyster Point Announces Enrollment of 1st Subject in Phase 2 Trial of OC-01
21 Jun 2021 //
GLOBENEWSWIRE
Oyster Point to Participate in the LifeSci Partners Genetic Medicines Summit
21 Jun 2021 //
GLOBENEWSWIRE
Adaptive Phage Therapeutics Announces Collaboration with Oyster Point Pharma
10 Jun 2021 //
BUSINESSWIRE
Oyster Point Pharma Announces Preclinical Study Results and Pipeline
03 Jun 2021 //
GLOBENEWSWIRE
Oyster Point Pharma Announces FDA Acceptance for Filing NDA for OC-01
02 Mar 2021 //
GLOBENEWSWIRE
Oyster Point Pharma Submits NDA to the USFDA for OC-01 (varenicline)
18 Dec 2020 //
GLOBENEWSWIRE
Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01
01 Dec 2020 //
GLOBENEWSWIRE
Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray
13 Nov 2020 //
GLOBENEWSWIRE
Oyster Point Pharma Announces Board of Directors Leadership Changes
08 Oct 2020 //
GLOBENEWSWIRE
Oyster Point Pharma announces phase 3 ONSET-2 study in dry eye disease
12 May 2020 //
PHARMABIZ
Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent
11 May 2020 //
GLOBENEWSWIRE
Oyster Pharma Announces Addition to the Russell 2000®, Russell 3000® Indexes
23 Dec 2019 //
GLOBE NEWSWIRE
Oyster Point Pharma Announces +Ve Top-Line Results From the Ph 1 “ZEN†Study
26 Nov 2019 //
GLOBE NEWSWIRE
Oyster Point Pharma Announces +ve Top-Line Results From Ph 1 “ZEN†Study
22 Nov 2019 //
GLOBE NEWSWIRE
